These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 12666442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
    Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
    [Abstract] [Full Text] [Related]

  • 3. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 5. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R, Sobra J, Kvasnicka J, Procházková R, Kvasilová M, Haas T.
    Cas Lek Cesk; 1996 Jul 26; 135(13):413-6. PubMed ID: 8925538
    [Abstract] [Full Text] [Related]

  • 6. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 2001 Dec 26; 39(12):551-7. PubMed ID: 11770837
    [Abstract] [Full Text] [Related]

  • 7. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 26; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 8. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun 26; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 9. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L, Szostak WB, Grzybowska B, Białobrzeska-Paluszkiewicz J, Wiśniewska B, Stolarska I.
    Kardiol Pol; 2004 Jun 26; 60(6):567-77. PubMed ID: 15334157
    [Abstract] [Full Text] [Related]

  • 10. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 26; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits.
    Zhao SP, Li J, Xu Z, Wu J, Li Q, Ye H.
    Clin Chim Acta; 2004 Nov 26; 349(1-2):81-6. PubMed ID: 15469859
    [Abstract] [Full Text] [Related]

  • 13. [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].
    Márk L, Márki-Zay J, Orosz I, Kondacs A, Erdei F, Katona A.
    Orv Hetil; 2003 Apr 20; 144(16):765-8. PubMed ID: 12778627
    [Abstract] [Full Text] [Related]

  • 14. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr 20; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 15. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
    Yesilbursa D, Serdar A, Saltan Y, Serdar Z, Heper Y, Guclu S, Cordan J.
    Kardiol Pol; 2005 Jun 20; 62(6):526-30. PubMed ID: 16123850
    [Abstract] [Full Text] [Related]

  • 16. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P, Méjean L, Lambert D, Wülfert E, Debry G.
    Nouv Presse Med; 1980 Dec 22; 9(49):3753-7. PubMed ID: 7208342
    [Abstract] [Full Text] [Related]

  • 17. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
    Skrha J, Stulc T, Hilgertová J, Weiserová H, Kvasnicka J, Ceska R.
    Eur J Pharmacol; 2004 Jun 16; 493(1-3):183-9. PubMed ID: 15189781
    [Abstract] [Full Text] [Related]

  • 18. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
    Zwaveling JH, Maring JK, Mulder AB, Bom VJ, van Ginkel RJ, Schraffordt Koops H, Girbes AR, Hoekstra HJ, van der Meer J.
    Cancer Res; 1996 Sep 01; 56(17):3948-53. PubMed ID: 8752162
    [Abstract] [Full Text] [Related]

  • 19. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Sep 01; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 20. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 01; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.